Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
ELVN-001 is made to look more like Terns’ TERN-701.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
But Tevimbra’s role looks shaky as adverse events loom.
Four months after yielding first-in-human data INCA33890 enters phase 3.
